The overarching goal of our research is the development of prognostic imaging signatures defining biomarkers of disease progression and response to therapy. Methods are developed in pre-clinical studies and translated to human clinical applications.
Due to the diversity of tissue characteristics and responses to therapy, there is a vital need to define disease beyond the traditional staging of location, size, and spread. We believe a better understanding of pathophysiology, protein and gene expression can guide optimized individualized therapy.
Our goals are to integrate state-of-the-art instrumentation and applications to facilitate technique development based on physics, chemistry, and molecular biology.
Our methods focus on MRI, but with additional integrated applications of optical and radionuclide imaging.